-
2024 CASH | ProfessorJianXiang Wang : Innovating Research and Standardizing Quality Control to Promote the Healthy Development of Hematology in China
Advancing the Discipline for Healthy Development “Oncology Frontier – Hematology Frontier“: With the Fourth China Hematology Development Conference (CASH) about to commence, as the perennial chairman of CASH, could you talk…
-
2024 CASH | Professor Hui Wei : Nurturing Growth in AML Treatment with Spring Breeze, Looking Forward to the Future of Immunotherapy
“Oncology Frontier – Hematology Frontier”: As the executive chair of the leukemia session at this conference, what significance do you think this meeting holds for advancing research and treatment in the…
-
2024 CASH | Professor Gang An : Continuous Innovation in CAR-T Therapy, A New Dawn in MM Treatment!
“Oncology Frontier – Hematology Frontier“: CAR-T cell therapy has been a hot topic in hematology in recent years. Could you discuss the current status of CAR-T cell therapy in the field…
-
2024 CASH | Professor ChunYan Ji : Significant Advances in Leukemia Treatment, Aiming to Achieve Treatment-Free Remission for More Patients
“Oncology Frontier – Hematology Frontier“: As the chairman of the “Leukemia” session, could you discuss the significant research advancements in the diagnosis and treatment of leukemia in recent years, especially in…
-
Dr. Nicholas Short: The Latest Therapeutic Advances in Acute Lymphoblastic Leukemia
Abstract: Dr. Nicholas Short delves into the forefront of advancements in the treatment of Acute Lymphoblastic Leukemia (ALL) at the EHA Congress 2023. He discusses the evolution of therapeutic strategies, particularly in B cell ALL, where various agents like blinatumomab, inotuzumab ozogamicin, and CD19 CAR T cell products have demonstrated notable efficacy. Notably, the focus…
-
Dr. Huang Huiqiang: Immune Therapy Era is Imminent for Extranodal NK/T Cell Lymphoma
Extranodal NK/T cell lymphoma (ENKTCL), nasal type, is a rare subtype prevalent in Asian populations and associated with the Epstein-Barr virus (EBV). Currently, patients’ prognosis remains poor, especially for relapsed/refractory (R/R) cases. From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) Annual Congress was held in Frankfurt, Germany. A selected oral presentation…
-
Dr. Hou Ming: BTK Inhibitor Ibrutinib Offer Limitless Prospects for ITP Treatment
Editor’s Note: From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) Congress was held in Frankfurt, Germany. During this conference, Dr. Hou Ming’s team at Qilu Hospital, Shandong University, China, presented the research findings on the use of the BTK inhibitor ibrutinib for primary immune thrombocytopenia (ITP) (abstract S299). To gain deeper…
-
Dr. Amir Fathi: The Latest Advances in Targeted Therapy for Acute Myeloid Leukemia
Abstract: In this interview, Dr. Amir Fathi provides insights into the impact of NPM1 mutations on the prognosis of acute myeloid leukemia (AML) patients, emphasizing the evolving nuances based on…
Connecting Medical Expertise through Media